View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, May 12 (HealthDay News) -- The U.S. Food and Drug Administration has announced the launch of a new program to educate health care providers regarding their role in making certain that advertisements and promotions for prescription drugs are truthful and not misleading.
The new program is administered through the agency's Division of Drug Marketing, Advertising, and Communications (DDMAC). Called the "Bad Ad Program," it will be launched in three phases. In phase 1, the DDMAC will interact with health care providers at medical conferences, and partner with medical societies to distribute educational materials. In phases 2 and 3, the agency will expand its joint efforts, and educational materials developed for phase 1 will be updated.
The FDA encourages health care providers to report any potential prescription drug marketing violations to the DDMAC. Reports can be submitted by e-mailing email@example.com or calling 1-877-RX-DDMAC.
"The Bad Ad Program will help health care providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency," Thomas Abrams, director of the DDMAC," said in a statement.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top